This is a monoclonal antibody targeting CEACAM6, a cell adhesion receptor overexpressed in pancreatic ductal adenocarcinoma (PDA) and other cancers. The antibody is designed to inhibit CEACAM6 function, which is implicated in anoikis resistance and tumor invasiveness. Preclinical studies have shown that the antibody has anti-PDA activity in an orthotopic mouse model.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
NABG-042 | Recombinant Anti-Human CEACAM6 VHH Single Domain Antibody | ELISA, IHC, FC, FuncS | Llama VHH |
TAB-004LC-VHH | Anti-Human CEACAM6 Recombinant Antibody (TAB-004LC-VHH) | ELISA, WB, FC, Inhib, FuncS, ICC, SPR | Single domain antibody |
There are currently no Customer reviews or questions for VS-0325-FY179. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.